Viagra(sildenafil)
Liqrev, Revatio, Viagra (sildenafil) is a small molecule pharmaceutical. Sildenafil was first approved as Viagra on 1998-03-27. It is used to treat pulmonary hypertension and vasculogenic impotence in the USA. It has been approved in Europe to treat erectile dysfunction and pulmonary hypertension. The pharmaceutical is active against cGMP-specific 3',5'-cyclic phosphodiesterase. In addition, it is known to target solute carrier organic anion transporter family member 2B1, ATP-binding cassette sub-family C member 5, solute carrier organic anion transporter family member 1B3, and cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| respiratory tract diseases | D012140 |
| urogenital diseases | D000091642 |
| cardiovascular diseases | D002318 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Liqrev, Revatio, Viagra (generic drugs available since 2012-11-06)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sildenafil citrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LIQREV | CMP Pharma | N-214952 RX | 2023-04-28 | 1 products, RLD, RS |
| VIAGRA | Viatris | N-020895 RX | 1998-03-27 | 3 products, RLD, RS |
| REVATIO | Viatris | N-021845 RX | 2005-06-03 | 1 products, RLD, RS |
| REVATIO | Viatris | N-022473 RX | 2009-11-18 | 1 products, RLD, RS |
| REVATIO | Viatris | N-203109 RX | 2012-08-30 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| liqrev | New Drug Application | 2023-04-30 |
| revatio | New Drug Application | 2020-12-28 |
| sildenafil | ANDA | 2023-06-16 |
| viagra | New Drug Application | 2021-07-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
| vasculogenic impotence | EFO_1001234 | D018783 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
SILDENAFIL CITRATE, REVATIO, VIATRIS | |||
| 2026-01-31 | M-287 | ||
HCPCS
Code | Description |
|---|---|
| S0090 | Sildenafil citrate, 25 mg |
Clinical
Clinical Trials
384 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 12 | 6 | 9 | 36 | 8 | 69 |
| Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 3 | 17 | 22 | 11 | 11 | 58 |
| Pulmonary arterial hypertension | D000081029 | 3 | 1 | 7 | 13 | 8 | 31 | ||
| Healthy volunteers/patients | — | 11 | 1 | — | 1 | 1 | 14 | ||
| Heart failure | D006333 | EFO_0003144 | I50 | 1 | 2 | 8 | 2 | — | 12 |
| Prostatic neoplasms | D011471 | C61 | — | 1 | 3 | 1 | 4 | 9 | |
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 2 | 1 | 1 | 3 | 8 |
| Persistent fetal circulation syndrome | D010547 | EFO_1001103 | P29.3 | 2 | 2 | 2 | 1 | 2 | 8 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 2 | 1 | 4 | 1 | 8 |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | — | 2 | 2 | 2 | — | 5 |
Show 39 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fetal growth retardation | D005317 | EFO_0000495 | — | 4 | 6 | — | — | 7 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 3 | 6 | 1 | — | — | 6 |
| Pulmonary fibrosis | D011658 | J84.10 | — | 3 | 2 | — | — | 4 | |
| Congenital heart defects | D006330 | HP_0001627 | Q24.9 | — | — | 1 | — | 3 | 4 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | 3 | 2 | — | 1 | 4 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 1 | — | 2 | — | — | 3 |
| Raynaud disease | D011928 | EFO_1001145 | I73.0 | 1 | 1 | 2 | — | — | 3 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | — | — | 1 | — | 1 | 2 |
| Covid-19 | D000086382 | U07.1 | 1 | 1 | 1 | — | — | 2 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | 1 | 2 | — | — | 2 |
Show 11 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Traumatic brain injuries | D000070642 | S06 | 2 | 2 | — | — | — | 4 | |
| Duchenne muscular dystrophy | D020388 | 2 | 2 | — | — | — | 4 | ||
| Post-concussion syndrome | D038223 | EFO_1001827 | F07.81 | 1 | 2 | — | — | — | 3 |
| Subarachnoid hemorrhage | D013345 | EFO_0000713 | I60 | 1 | 2 | — | — | — | 3 |
| Intracranial vasospasm | D020301 | EFO_1000994 | G45.9 | 1 | 2 | — | — | — | 3 |
| Bronchopulmonary dysplasia | D001997 | P27.8 | — | 2 | — | — | — | 2 | |
| Urinary incontinence | D014549 | HP_0000020 | R32 | 1 | 1 | — | — | — | 2 |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | 2 | — | — | — | 2 |
| Prostatic hyperplasia | D011470 | EFO_0000284 | N40 | 1 | 1 | — | — | — | 2 |
| Brain concussion | D001924 | S06.0 | 1 | 1 | — | — | — | 2 |
Show 28 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 2 | — | — | — | — | 2 |
| Migraine with aura | D020325 | EFO_0005295 | G43.1 | 1 | — | — | — | 1 | 2 |
| Neoplasms | D009369 | C80 | 1 | — | — | — | 1 | 2 | |
| Hand-foot syndrome | D060831 | EFO_1001893 | 1 | — | — | — | — | 1 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Gastrointestinal neoplasms | D005770 | C26.9 | 1 | — | — | — | — | 1 | |
| Sarcoma | D012509 | 1 | — | — | — | — | 1 | ||
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Female genital neoplasms | D005833 | 1 | — | — | — | — | 1 | ||
| Hepatitis c | D006526 | B19.2 | 1 | — | — | — | — | 1 |
Show 16 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 2 | 2 |
| Pregnancy complications | D011248 | — | — | — | — | 2 | 2 | ||
| High-risk pregnancy | D018566 | — | — | — | — | 1 | 1 | ||
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | — | — | — | — | 1 | 1 |
| Iron overload | D019190 | — | — | — | — | 1 | 1 | ||
| Drug interactions | D004347 | — | — | — | — | 1 | 1 | ||
| Penile neoplasms | D010412 | C60 | — | — | — | — | 1 | 1 | |
| Nephrogenic diabetes insipidus | D018500 | N25.1 | — | — | — | — | 1 | 1 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
Show 9 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | SILDENAFIL |
| INN | sildenafil |
| Description | Sildenafil, sold under the brand name Viagra, among others, is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is unclear if it is effective for treating sexual dysfunction in women. It is taken by mouth or by injection into a vein. Onset is typically within twenty minutes and lasts for about two hours.
|
| Classification | Small molecule |
| Drug class | phosphodiesterase type 5 inhibitors (PDE5) inhibitors: (PDE5) inhibitors containing a sulfonamide moiety |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12 |
Target
Agency Approved
PDE5A
PDE5A
Organism
Homo sapiens
Gene name
PDE5A
Gene synonyms
PDE5
NCBI Gene ID
Protein name
cGMP-specific 3',5'-cyclic phosphodiesterase
Protein synonyms
CGB-PDE, cGMP-binding cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase, cGMP-binding cGMP-specific phosphodiesterase, cGMP-specific phosphodiesterase PDE5A2, cGMP-specific phosphodiesterase type 5A, phosphodiesterase 5A, cGMP-specific, phosphodiesterase isozyme 5
Uniprot ID
Mouse ortholog
Pde5a (242202)
cGMP-specific 3',5'-cyclic phosphodiesterase (Q8CG03)
Alternate
SLCO2B1
SLCO2B1
ABCC5
ABCC5
SLCO1B3
SLCO1B3
PDE6C
PDE6C
Organism
Homo sapiens
Gene name
SLCO2B1
Gene synonyms
KIAA0880, OATP2B1, OATPB, SLC21A9
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 2B1
Protein synonyms
OATP-B, OATP-RP2, OATP2B1, OATPRP2, Organic anion transporter B, Organic anion transporter polypeptide-related protein 2, Organic anion transporting polypeptide 2B1, solute carrier family 21 (organic anion transporter), member 9, Solute carrier family 21 member 9
Uniprot ID
Mouse ortholog
Slco2b1 (101488)
solute carrier organic anion transporter family member 2B1 (Q8BXB6)
Variants
Clinical Variant
No data
Financial
Viagra - Viatris
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Viagra - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Revatio - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Sildenafil - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 19,520 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
5,747 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more